LIFE SCIENCES
Heru Biotechnology Research Center
Helping life sciences companies bring innovative, personalized therapies to patients faster through the application of real-world clinico-genomic data and our extensive health systems network.
Applying Population Genomics and Viral Surveillance to Enable the Scale of Personalized, Integrated Life Sciences Solutions.
Helix provides a comprehensive platform of solutions that can be used to turn our proprietary clinico-genomic database of Exome+ sequencing data and deep phenotypic data on recontactable individuals into actionable insights for your organization. These solutions also leverage our extensive network of health system partnerships to accelerate efforts across the drug development process from discovery, all the way to commercialization.
Accelerate Your Efforts Across the Drug Development Process
Discovery & Preclinical
Support target identification and biomarker discovery.
Clinical Development
Phase I – Phase II – Phase III
Use genomics to identify better patient populations to accelerate enrollment and reduce trial length. Develop better patients analytics to prepare for both market access and product launch plans.
Commercialization
Phase IV
Leverage genomics and our health system network to support Phase IV studies, surveillance efforts and commercialization.
Overview
Objectives
- Conduct detailed studies on human DNA to identify physical and cognitive potential, as well as genetic predispositions to diseases.
- Develop new technologies and methodologies in biotechnology.
- Preserve the DNA of local fauna and flora from Peru and South America, including marine species.
- Implement genetic conservation programs and environmental sustainability initiatives.
- Offer genetic counseling services for reproduction, helping individuals find partners with the highest genetic potential.
- Create detailed genetic profiles to optimize desired traits such as health, longevity, personality, cognitive abilities, and beauty.
- Boost local and regional economic development by creating high-quality jobs and attracting investments.
- Promote education and professional development in biotechnology and genetics.
Facilities and Equipment
- Laboratories equipped with state-of-the-art technology for genetic analysis and advanced biotechnology.
- Specialized work areas for research in molecular biology, bioinformatics, and systems biology.
- Robust infrastructure to store and process large volumes of genetic data.
- Advanced security systems to protect sensitive genetic information.
- Spaces dedicated to the preservation and study of plants and animals.
- Controlled greenhouses for experiments and species conservation.
- Conference rooms and classrooms for staff training and scientific events.
- Continuous training programs for researchers and industry professionals.
Expected Impact
- Significant advances in genetic and biotechnological knowledge.
- Development of new technologies and methodologies applicable to health, agriculture, and conservation.
- Creation of high-quality jobs.
- Attraction of national and international investments to Peru’s biotechnology sector.
- Improvement of population health and well-being through genetic applications.
- Promotion of an active and collaborative scientific community in Peru.
- Preservation of local and regional biodiversity.
- Contribution to environmental sustainability through genetic conservation practices.
Enabling the Application of Genomics for Life Sciences Companies at a Scale and Depth Not Previously Possible
Versatile
Exome+®
Assay
Go beyond GWAS
Panel-grade clinical exome provides the performance of a targeted panel, the breadth of a microarray, and the completeness of an exome — all in one assay
Unparalleled
Population Reach
Expand in real time
Unheard-of scale and reach into a variety of populations with our network of population genomics programs across the United States
Genetic Research Expertise
Get started quickly
Analytic, genetic and scientific expertise working with large clinico-genomic datasets through our database of consented patients
Unique Real-World Datasets
Customized to your needs
Diverse clinico-genomic data, continuously growing in scale, with longitudinal EHR data regularly refreshed
The analysis of these large datasets in collaboration with Renown could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.
John McHutchison, AO, MD
Chief Scientific Officer and Head of Research and Development, Gilead Sciences
Get in Touch
We invite investors, researchers, and organizations to join the Genesis Project. Together, we can explore the vast potential of human genetics and ensure a healthier and more prosperous future.
For more information and to participate, visit: www.herugenomics.com or contact us directly at info@herugenomics.com.
- Elevating Life Forms to New Heights.
- Contact us:
- © 2016-2024 Heru, Inc. All rights reserved.
- Customer Support: (777) 777 7777
- Partnership Proposals: (555) 555 5555
- Monday - Friday: 6 AM – 6 PM (Pacific)
Heru, the Heru logo, Exome+, and Sequence Once, Query Often are trademarks of Heru Genomics Inc.
Contact Us
- Privacy Policy
- Terms of Service
- Notice of Privacy Practices